Nkarta (NKTX) Projected to Post Earnings on Thursday

Nkarta (NASDAQ:NKTX) is expected to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Nkarta to post earnings of ($0.39) per share for the quarter.

Nkarta Stock Performance

Shares of NKTX stock opened at $1.82 on Thursday. Nkarta has a 52-week low of $1.57 and a 52-week high of $13.90. The company has a market capitalization of $128.44 million, a PE ratio of -0.97 and a beta of 0.90. The business’s fifty day moving average is $2.18 and its 200 day moving average is $3.17.

Insider Buying and Selling at Nkarta

In other news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the transaction, the chief executive officer now owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. This represents a 5.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 8.70% of the company’s stock.

Analysts Set New Price Targets

Separately, Mizuho reduced their target price on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $15.00.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.